Trial Profile
Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-In Cohort to Establish Activity in Patients With Metastatic TNBC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mirvetuximab soravtansine (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 28 Sep 2020 Results published in the Investigational New Drugs
- 14 Jan 2020 Status changed from active, no longer recruiting to completed.
- 21 Aug 2019 Planned End Date changed from 1 Jun 2020 to 30 Jun 2020.